Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basel Medical GroupBMGL +4.98%17 Debt-to-Equity is 1.43 as of Dec. 2025, which is 54% above its 10-year median of 0.93. GuruFocus rates BMGL with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 556 Healthcare Providers & Services companies, Basel Medical Group ranks worse than 82.01% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Basel Medical Group's Debt-to-Equity or its related term are showing as below:
BMGL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.57 Med: 0.93 Max: 2.74
Current: 1.43
During the past 4 years, the highest Debt-to-Equity Ratio of Basel Medical Group was 2.74. The lowest was 0.57. And the median was 0.93.
BMGL's Debt-to-Equity is ranked worse than 82.01% of 556
companies
in the Healthcare Providers & Services industry
Industry Median: 0.405
vs BMGL: 1.43
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Basel Medical Group Debt-to-Equity Related Terms
Basel Medical Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Basel Medical Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMGL vs BICX, SYRA, AMS: Debt-to-Equity Comparison
For the Medical Care Facilities subindustry, Basel Medical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basel Medical Group Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Basel Medical Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Basel Medical Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basel Medical Group (BMGL) has a Debt-to-Equity of 1.43 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Basel Medical Group and its competitors. This is 54% above median its historical median of 0.93. Over the past decade, Basel Medical Group's Debt-to-Equity has ranged from 0.57 to 2.74. According to the industry distribution chart, Basel Medical Group ranks #456 out of 556 companies in the Healthcare Providers & Services industry, placing it in the top 82%.
Is Basel Medical Group's Debt-to-Equity too high?
Basel Medical Group's current Debt-to-Equity of 1.43 is 54% above median its 10-year median of 0.93. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 2.74. The Healthcare Providers & Services industry median Debt-to-Equity is 0.41. Basel Medical Group's value of 1.43 is 253.1% above this industry median. Based on the distribution chart, Basel Medical Group ranks #456 out of 556 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Basel Medical Group has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Basel Medical Group's Debt-to-Equity compare to BICX and SYRA?
According to the Healthcare Providers & Services industry distribution chart, Basel Medical Group ranks #456 out of 556 companies for Debt-to-Equity. This places Basel Medical Group in the lower half of its industry. The industry median Debt-to-Equity is 0.41. Basel Medical Group's value of 1.43 is 253.1% above this benchmark. Historically, Basel Medical Group's own Debt-to-Equity has ranged from 0.57 to 2.74 over the past decade. While the company's 10-year median is 0.93 vs. the industry median of 0.41, Basel Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.41, based on 556 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basel Medical Group's current Debt-to-Equity of 1.43 is 253.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Basel Medical Group and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basel Medical Group's current Debt-to-Equity is 1.43, which is 54% above median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basel Medical Group stock overvalued right now?
Basel Medical Group (BMGL) has a current Debt-to-Equity of 1.43. The current Debt-to-Equity is 1.43, which is 54% above median its 10-year median of 0.93 and 253.1% above the Healthcare Providers & Services industry median of 0.41. Basel Medical Group's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Basel Medical Group (BMGL), the current Debt-to-Equity is 1.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. The services provided by clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women's health and neurosurgical conditions and clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services. Key revenue is generated from Singapore.
17GF Score
Get the complete analysis for BMGL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMGL has been successfully added to your 
